Myocardial fibrosis found on CMR in patients with hypertension associated with worse outcomes

A recent study conducted by the National Heart Centre Singapore (NHCS) discovered that myocardial fibrosis is associated with worse cardiovascular outcomes in patients with hypertension. Myocardial fibrosis is an important prognostic marker in the development of adverse cardiovascular events, such as heart failure and death.

In Singapore, the prevalence of hypertension has shown an increase from 24.2% in 2017 to 35.5% in 2019 to 20201 and it is a major cause of ischemic heart disease, strokes and heart failure2,3,4. Although conventional medical treatment is able to control one's blood pressure, it does not completely ameliorate or eliminate risks of cardiovascular disease. For instance, about 30% of these cardiovascular events occur in patients with well-controlled blood pressure4.

In this prospective and observational study, titled REMODEL (Response of the Myocardium to Hypertrophic Conditions in the Adult Population)5 led by Associate Professor Calvin Chin, Clinician Scientist and Senior Consultant from the Department of Cardiology at NHCS, CMR was performed in close to 800 patients with hypertension.

The patients were followed up for adverse cardiovascular events over an average period of more than three years. CMR is a useful diagnostic tool which detects heart structural abnormalities and quantifies fibrosis without the invasive sampling of heart muscle tissues.

Myocardial fibrosis typically happens in patients with previous heart attacks. Correspondingly, patients in the REMODEL study did not have previous heart attacks, hence any occurrence of myocardial fibrosis have been deduced to that of patient's susceptibility to blood pressure, and other reasons such as genetic predisposition and other medical co-morbidities like diabetes.

"Although anecdotal reports have previously shown the presence of heart muscle scarring in patients with hypertension, this is the first study that confirms the adverse association between scarring of heart muscle and the cardiovascular outcomes in patients with hypertension. We found that heart muscle scarring is a stronger predictor of adverse outcomes even after correcting for patients' age, sex and systolic blood pressures," said Assoc Prof Calvin Chin, who is also the Director of Cardiac Magnetic Resonance Imaging at NHCS.

The research team further found that the heart muscle response to hypertension in patients is heterogeneous or diverse, whereby while two patients may have similar blood pressure, their myocardial characteristics can be different. This presents opportunities to tailor and personalise treatment for hypertensive patients who have heart muscle scarring to reduce potential risk of future cardiovascular events, beyond lowering their blood pressure and achieving their blood pressure targets.

Following these findings that were published this year in the medical Journal Hypertension, Assoc Prof Calvin Chin and the team are now into the next phase of an ongoing trial REVERSE-LVH6 to assess the potential of reversing heart muscle scarring, through the use of specific therapies targeted at fibrosis in patients with hypertensive heart disease.

REVERSE-LVH is a randomised controlled study to compare the efficacy of medications in regressing myocardial fibrosis. Patients recruited in the study would undergo CMR after a year to quantity the amount of myocardial fibrosis detected before and after treatment.

"Using CMR, a non-invasive tool to detect fibrosis has potential to improve risk-stratification of patients with hypertension. Targeted anti-fibrotic intervention, if proven effective, could have direct impact on clinical practice and help selected patients with hypertension lead better quality of life and have better health outcomes," said Assoc Prof Calvin Chin.

Reference:

Nithin R Iyer, Thu-Thao Le, Michelle S L Kui, Hak-Chiaw Tang, Chee-Tang Chin, Soon-Kieng Phua, Jennifer A Bryant, Chee-Jian Pua, Briana Ang, Desiree-Faye Toh, Tar-Choon Aw, Chi-Hang Lee, Stuart A Cook, Martin Ugander, Calvin W L Chin, DOI: 10.1161/HYPERTENSIONAHA.122.19225